Key facts
- Phenotypeca’s last known valuation is $6.0M (Jan 2025).
- It has raised $2.3M; the latest was Angel (individual) ($1.2M) in Jan 2025.
- Notable investors include Innovate UK, Enterprise Investment Scheme, SEIS Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Phenotypeca
- ·The full record, as it builds
Funding rounds
No funding rounds for Phenotypeca are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Phenotypeca
Operator of a synthetic biology company intended to provide novel biologics production strains for recombinant proteins. The company applies proprietary QTL strain optimisation technology to create recombinant biosimilars, vaccines, and cosmeceutical ingredients to deliver manufacturing strains capable of secreting difficult-to-express proteins at high yields, enabling healthcare industries to create strains stable at industrial scale, and suited to the demands of modern biomanufacturing.
- Sector
- Healthcare
- HQ
- Nottingham, United Kingdom
- Founded
- 2018
- Employees
- 18
- Website
- phenotypeca.com/
- Ownership
- Privately Held (backing)
Phenotypeca doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Phenotypeca shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Phenotypeca in its N-PORT filings yet. We sweep new filings monthly.